Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 7
2005 2
2010 1
2011 1
2012 2
2013 2
2014 4
2015 14
2016 10
2017 13
2018 17
2019 16
2020 14
2021 16
2022 21
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Delafloxacin: A Review in Community-Acquired Pneumonia.
Lee A, Lamb YN, Shirley M. Lee A, et al. Drugs. 2022 Jun;82(8):913-923. doi: 10.1007/s40265-022-01725-z. Epub 2022 Jun 16. Drugs. 2022. PMID: 35708893 Review.
Delafloxacin kills a wide range of bacteria, including some drug-resistant variants. During a trial in adults with CAP, delafloxacin was as effective as moxifloxacin (also a fluoroquinolone antibacterial). ...
Delafloxacin kills a wide range of bacteria, including some drug-resistant variants. During a trial in adults with CAP, delafloxac …
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway.
Zusso M, Lunardi V, Franceschini D, Pagetta A, Lo R, Stifani S, Frigo AC, Giusti P, Moro S. Zusso M, et al. J Neuroinflammation. 2019 Jul 18;16(1):148. doi: 10.1186/s12974-019-1538-9. J Neuroinflammation. 2019. PMID: 31319868 Free PMC article. Review.
METHODS: The putative binding mode of five FQs [ciprofloxacin (CPFX), levofloxacin (LVFX), moxifloxacin, ofloxacin, and delafloxacin] to TLR4-MD-2 was determined using molecular docking simulations. ...
METHODS: The putative binding mode of five FQs [ciprofloxacin (CPFX), levofloxacin (LVFX), moxifloxacin, ofloxacin, and delafloxacin] …
Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia.
Bassetti M, Melchio M, Giacobbe DR. Bassetti M, et al. Expert Rev Anti Infect Ther. 2022 May;20(5):649-656. doi: 10.1080/14787210.2021.2020098. Epub 2021 Dec 28. Expert Rev Anti Infect Ther. 2022. PMID: 34913817 Review.
AREAS COVERED: The present narrative review summarizes the available data on the use of delafloxacin for the treatment of community-acquired bacterial pneumonia (CABP). ...The results of the DEFINE-CABP phase-3 randomized controlled trial have shown noninferiority of de …
AREAS COVERED: The present narrative review summarizes the available data on the use of delafloxacin for the treatment of community-a …
Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.
Shiu J, Ting G, Kiang TK. Shiu J, et al. Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):305-317. doi: 10.1007/s13318-018-0520-8. Eur J Drug Metab Pharmacokinet. 2019. PMID: 30324277 Review.
Delafloxacin has recently received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections. This article provides a balanced and comprehensive systematic critique of the literature in order to provide an up-to …
Delafloxacin has recently received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin …
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ. Scott LJ. Drugs. 2020 Aug;80(12):1247-1258. doi: 10.1007/s40265-020-01358-0. Drugs. 2020. PMID: 32666425 Free PMC article. Review.
Delafloxacin (intravenous and oral formulations) is approved in several countries for the treatment of adults with ABSSSIs (featured indication). ...Relative to vancomycin + aztreonam (a non-FQ regimen), delafloxacin treatment was not associated with an increased ri …
Delafloxacin (intravenous and oral formulations) is approved in several countries for the treatment of adults with ABSSSIs (featured …
Delafloxacin: First Global Approval.
Markham A. Markham A. Drugs. 2017 Sep;77(13):1481-1486. doi: 10.1007/s40265-017-0790-5. Drugs. 2017. PMID: 28748399 Free PMC article. Review.
Delafloxacin (Baxdela) is a fluoroquinolone antibacterial with activity against both gram-positive and gram-negative pathogens being developed by Melinta Therapeutics. ...This article summarizes the milestones in the development of delafloxacin leading to this first …
Delafloxacin (Baxdela) is a fluoroquinolone antibacterial with activity against both gram-positive and gram-negative pathogens being …
Delafloxacin for the treatment of respiratory and skin infections.
Bassetti M, Della Siega P, Pecori D, Scarparo C, Righi E. Bassetti M, et al. Expert Opin Investig Drugs. 2015 Mar;24(3):433-42. doi: 10.1517/13543784.2015.1005205. Epub 2015 Jan 21. Expert Opin Investig Drugs. 2015. PMID: 25604710 Review.
EXPERT OPINION: The profile of delafloxacin offers several advantages. Delafloxacin presents a broad spectrum of activity against pathogens involved in respiratory infections and complicated skin and skin structure infections (SSSIs), including methicillin-resistant …
EXPERT OPINION: The profile of delafloxacin offers several advantages. Delafloxacin presents a broad spectrum of activity agai …
What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.
Cho JC, Crotty MP, White BP, Worley MV. Cho JC, et al. Pharmacotherapy. 2018 Jan;38(1):108-121. doi: 10.1002/phar.2050. Epub 2017 Nov 23. Pharmacotherapy. 2018. PMID: 29059465 Review.
During phase 3 trials, the most common side effects associated with delafloxacin were gastrointestinal (nausea, diarrhea). Unlike other fluoroquinolones, there does not seem to be a risk of QTc prolongation or phototoxicity with delafloxacin. The availability of bot …
During phase 3 trials, the most common side effects associated with delafloxacin were gastrointestinal (nausea, diarrhea). Unlike oth …
Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.
Saravolatz LD, Stein GE. Saravolatz LD, et al. Clin Infect Dis. 2019 Mar 5;68(6):1058-1062. doi: 10.1093/cid/ciy600. Clin Infect Dis. 2019. PMID: 30060092 Review.
Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. ...When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile. ...
Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. ...When compared to combination t …
Clinical review of delafloxacin: a novel anionic fluoroquinolone.
Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Mogle BT, et al. J Antimicrob Chemother. 2018 Jun 1;73(6):1439-1451. doi: 10.1093/jac/dkx543. J Antimicrob Chemother. 2018. PMID: 29425340 Review.
The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in acidic environments. ...Similar to other FQs, delafloxacin is available in both intravenous and oral formulations, but differs in that delafloxacin exerts …
The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in acidic environments. ...Simi …
146 results